These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 18796354)

  • 1. Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors.
    Ghosh AK; Gong G; Grum-Tokars V; Mulhearn DC; Baker SC; Coughlin M; Prabhakar BS; Sleeman K; Johnson ME; Mesecar AD
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5684-8. PubMed ID: 18796354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based design, synthesis, and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome-coronavirus papain-like protease.
    Ghosh AK; Takayama J; Aubin Y; Ratia K; Chaudhuri R; Baez Y; Sleeman K; Coughlin M; Nichols DB; Mulhearn DC; Prabhakar BS; Baker SC; Johnson ME; Mesecar AD
    J Med Chem; 2009 Aug; 52(16):5228-40. PubMed ID: 19645480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand X-ray structure and biological evaluation.
    Ghosh AK; Takayama J; Rao KV; Ratia K; Chaudhuri R; Mulhearn DC; Lee H; Nichols DB; Baliji S; Baker SC; Johnson ME; Mesecar AD
    J Med Chem; 2010 Jul; 53(13):4968-79. PubMed ID: 20527968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro.
    Chen L; Gui C; Luo X; Yang Q; Günther S; Scandella E; Drosten C; Bai D; He X; Ludewig B; Chen J; Luo H; Yang Y; Yang Y; Zou J; Thiel V; Chen K; Shen J; Shen X; Jiang H
    J Virol; 2005 Jun; 79(11):7095-103. PubMed ID: 15890949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based design and synthesis of highly potent SARS-CoV 3CL protease inhibitors.
    Shao YM; Yang WB; Peng HP; Hsu MF; Tsai KC; Kuo TH; Wang AH; Liang PH; Lin CH; Yang AS; Wong CH
    Chembiochem; 2007 Sep; 8(14):1654-7. PubMed ID: 17722121
    [No Abstract]   [Full Text] [Related]  

  • 6. Quaternary structure, substrate selectivity and inhibitor design for SARS 3C-like proteinase.
    Lai L; Han X; Chen H; Wei P; Huang C; Liu S; Fan K; Zhou L; Liu Z; Pei J; Liu Y
    Curr Pharm Des; 2006; 12(35):4555-64. PubMed ID: 17168761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL(pro) inhibitors.
    Regnier T; Sarma D; Hidaka K; Bacha U; Freire E; Hayashi Y; Kiso Y
    Bioorg Med Chem Lett; 2009 May; 19(10):2722-7. PubMed ID: 19362479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular docking identifies the binding of 3-chloropyridine moieties specifically to the S1 pocket of SARS-CoV Mpro.
    Niu C; Yin J; Zhang J; Vederas JC; James MN
    Bioorg Med Chem; 2008 Jan; 16(1):293-302. PubMed ID: 17931870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a red-shifted fluorescence-based assay for SARS-coronavirus 3CL protease: identification of a novel class of anti-SARS agents from the tropical marine sponge Axinella corrugata.
    Hamill P; Hudson D; Kao RY; Chow P; Raj M; Xu H; Richer MJ; Jean F
    Biol Chem; 2006 Aug; 387(8):1063-74. PubMed ID: 16895476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.
    Báez-Santos YM; St John SE; Mesecar AD
    Antiviral Res; 2015 Mar; 115():21-38. PubMed ID: 25554382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and evaluation of inhibitors for severe acute respiratory syndrome 3C-like protease based on phthalhydrazide ketones or heteroaromatic esters.
    Zhang J; Pettersson HI; Huitema C; Niu C; Yin J; James MN; Eltis LD; Vederas JC
    J Med Chem; 2007 Apr; 50(8):1850-64. PubMed ID: 17381079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
    Akaji K; Konno H
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of SARS-CoV 3CL protease by flavonoids.
    Jo S; Kim S; Shin DH; Kim MS
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):145-151. PubMed ID: 31724441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of cinanserin analogs as severe acute respiratory syndrome coronavirus 3CL protease inhibitors.
    Yang Q; Chen L; He X; Gao Z; Shen X; Bai D
    Chem Pharm Bull (Tokyo); 2008 Oct; 56(10):1400-5. PubMed ID: 18827378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substrate specificity profiling and identification of a new class of inhibitor for the major protease of the SARS coronavirus.
    Goetz DH; Choe Y; Hansell E; Chen YT; McDowell M; Jonsson CB; Roush WR; McKerrow J; Craik CS
    Biochemistry; 2007 Jul; 46(30):8744-52. PubMed ID: 17605471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor.
    Yang S; Chen SJ; Hsu MF; Wu JD; Tseng CT; Liu YF; Chen HC; Kuo CW; Wu CS; Chang LW; Chen WC; Liao SY; Chang TY; Hung HH; Shr HL; Liu CY; Huang YA; Chang LY; Hsu JC; Peters CJ; Wang AH; Hsu MC
    J Med Chem; 2006 Aug; 49(16):4971-80. PubMed ID: 16884309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: design, synthesis, biological evaluation, and docking studies.
    Thanigaimalai P; Konno S; Yamamoto T; Koiwai Y; Taguchi A; Takayama K; Yakushiji F; Akaji K; Chen SE; Naser-Tavakolian A; Schön A; Freire E; Hayashi Y
    Eur J Med Chem; 2013 Oct; 68():372-84. PubMed ID: 23994330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-throughput screening identifies inhibitors of the SARS coronavirus main proteinase.
    Blanchard JE; Elowe NH; Huitema C; Fortin PD; Cechetto JD; Eltis LD; Brown ED
    Chem Biol; 2004 Oct; 11(10):1445-53. PubMed ID: 15489171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug design targeting the main protease, the Achilles' heel of coronaviruses.
    Yang H; Bartlam M; Rao Z
    Curr Pharm Des; 2006; 12(35):4573-90. PubMed ID: 17168763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitor design for SARS coronavirus main protease based on "distorted key theory".
    Du QS; Sun H; Chou KC
    Med Chem; 2007 Jan; 3(1):1-6. PubMed ID: 17266617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.